Lakewood-Amedex (LABT) Debuts on Nasdaq via Direct Listing

Lakewood-Amedex Goes Public on Nasdaq

Lakewood-Amedex Biotherapeutics Inc. has commenced trading on the Nasdaq Capital Market under the ticker symbol LABT through a direct listing. The company focuses on developing antimicrobials for infectious diseases.

The listing marks a significant milestone, enabling the company to accelerate the development of its Bisphosphocin class of compounds, according to Chairman Doug Manion, M.D.

Strategic Focus on Infectious Diseases

The clinical-stage biotech company is advancing its lead product, Nu-3, a topical treatment for infected diabetic foot ulcers. This market is significant, with approximately 40 million people in the U.S. living with diabetes, a third of whom are at risk of developing such ulcers.

About half of these ulcers become infected, highlighting the need for effective antimicrobial treatments like Nu-3.

Clinical Trials and Market Impact

With the new listing, Lakewood-Amedex plans to initiate a Phase 2a clinical trial for Nu-3. The product is designed to eliminate bacteria, including resistant pathogens and biofilms.

Initial exploratory trials have shown positive antimicrobial response trends and improved wound healing without safety signals, positioning the company for its next phase of clinical studies.

Summary

The direct listing provides Lakewood-Amedex with increased visibility and access to capital markets. Investors will be closely watching the progress of the upcoming Phase 2a safety and dose-response study for its lead product, Nu-3.

FAQ

Q: What is Lakewood-Amedex's stock ticker?
A: The company trades on the Nasdaq under the ticker symbol LABT.

Q: What is the company's lead product?
A: Its lead product is Nu-3, a treatment for infected diabetic foot ulcers.

Source: Investing.com